Intra-Prostate Cancer Vaccine Inducer
Abstract
Substantial progress has been made in creating a simple, feasible method to induce an anti-cancer immune response in prostate cancers or metastases by manipulating the regulation of the immune response. Cancer cells are transformed into antigen presenting cells by inducing of the MHC class II molecules and suppressing the co-induced immunoregulatory Ii protein with antisense or siRNA methods. The resulting anticancer immune response is profound, curing up to 80% of mice with established prostate tumors, transplanted into their normal prostates. The important achievement of this past year has been to design, synthesize and validate two second generation reagents, for mice and humans, that are more potent, simpler to use, and set the stage for definite preclinical validation in mice, and with human tumors in tissue culture. Substantial improvement on the reagent of the original grant proposal was achieved by a) tripling the expression of the reverse gene construct which suppresses Ii protein expression, and b) by both chemical and plasmid genetic forms of small inhibitory RNA, which achieve the same end, but with surprising potency. These substantial technical advances (under Task 1 and 2) set the stage for advancement toward clinical trails (when justified by data from next year's effort).
Document Details
- Document Type
- Technical Report
- Publication Date
- Feb 01, 2005
- Accession Number
- ADA468160
Entities
People
- Robert E. Humphreys